EYE CARE'S #1 PODCAST NETWORK

Low-Dose Atropine Not FDA Approved: What the STAR Study Means for Today’s Myopia Control Practices

The topic of low-dose atropine, not FDA-approved, has become one of the most important conversations in pediatric eye care this year, especially as clinicians turn to the STAR Study for clarity on atropine’s role in modern myopia control. The STAR Study is the largest and most ethnically diverse atropine study to date, evaluating 0.01% and 0.03% atropine versus placebo in more than 800 children across three countries.

Subscribe to Defocus Media

Join a community of professionals dedicated to innovation and excellence. Don’t miss out on the insights that could redefine your practice—tune in and be inspired!

spot_imgspot_img

Must watch

Our Industry Partners